Tissue Engineered Vascular Grafts

The Graft That Grows

Nationwide Children’s Hospital is home to the pioneering inventors of the tissue-engineered vascular graft (TEVG) a landmark advance with the potential to transform care for children undergoing the Fontan operation. Built on decades of innovation and advanced through Nationwide Children’s research and clinical leadership, these grafts form living, flexible blood vessels that grow with the child. Currently being evaluated in a clinical trial, the technology has received Breakthrough Device Designation from the U.S. Food and Drug Administration.

Stay Up to Date

The Clinical Opportunity

A New Approach to Advance Outcomes

TEVGs are bioresorbable scaffolds seeded with the patient’s own cells that support the body's ability to grow a new blood vessel that we call a neovessel. After six months to a year, the scaffold has completely resorbed, leaving only tissue that structurally and functionally resembles a native blood vessel.

Decades of research support our TEVG, showing that it outperforms standard of care conduits by resisting calcification and growing with the child, reducing the number of interventions over the patient's lifespan.

Medical illustration showing red and white blood cells flowing through a blood vessel.

Designed for Better Flow

Compliant tissue optimizes laminar flow in the vessel, like a native blood vessel, helping protect the liver, kidneys and other organs.

Smiling young girl being examined with a stethoscope by a pediatric healthcare provider.

Grows With the Child

The neovessels that result from the TEVG grow with the child, helping ensure the graft remains the right size over time.

Laboratory researchers wearing protective clothing work inside a sterile laboratory environment. 

Strong Preclinical Data Currently Under Clinical Investigation 

Clinical trial and animal studies have demonstrated an outstanding safety profile.

Clinical Translation

From Research Concept to Clinical Translation

Christopher Breuer, MD, director of the Center for Regenerative Medicine at Nationwide Children’s and co-inventor of the TEVG, introduces the technology and his vision for the future.

Research Timeline

Decades in the Making

The TEVG story spans more than 30 years of research, translation, collaboration and clinical development.

1994

Beginning a Collaboration 

Christopher Breuer, MD, and Toshiharu Shinoka, MD, PhD, meet at Harvard University and begin their tissue engineering work together.

2012

First-in-Human U.S. Implant

Drs. Breuer and Shinoka implant the first vascular graft in a human in the United States as part of a landmark clinical trial.

2012

Program Moves to Nationwide Children’s

After the first patient, Drs. Breuer and Shinoka move to Nationwide Children’s Hospital where they enroll 3 more patients in the first clinical trial.

2014

First Clinical Trial Closes

The first clinical trial closed early because of graft narrowing. Those patients received additional treatment and are still doing well.

2020

TEVG2 Clinical Trial Opens

The single arm clinical trial is evaluating the safety and efficacy of the second generation TEVG as vascular conduits for extracardiac total cavopulmonary connection.

2023

FDA Breakthrough Device Designation

The TEVG program receives Breakthrough Device Designation from the U.S. Food and Drug Administration.

2025

Neovessel Biosciences Forms

Nationwide Children's launches Neovessel Biosciences, a startup company to advance the technology.

2026

National Scientific Recognition

Dr. Breuer gives a plenary presentation about TEVG at the American Heart Association Annual Scientific Meeting.

Looking Forward

Expanding Access

Ongoing work is focused on advancing the technology toward broader availability for children who may benefit.

Scroll horizontally to explore the timeline →

Leadership, Legacy and Collaboration

The People Behind the Progress

TEVG development has been shaped by clinical leadership, scientific partnership and a multidisciplinary team committed to advancing pediatric care.

Christopher Breuer, MD

Christopher Breuer, MD

Co Inventor of the TEVG

Director of the Center for Regenerative Medicine at Nationwide Children’s and chief scientific officer of Neovessel.

Meet Dr. Breuer
Mark Galantowicz, MD

Mark Galantowicz, MD

Principal Investigator, TEVG Trial

Cardiothoracic surgeon, co director of The Heart Center at Nationwide Children’s and surgical director of Neovessel.

Meet Dr. Galantowicz
Toshiharu Shinoka, MD, PhD

Toshiharu Shinoka, MD, PhD

Co Inventor of the TEVG

Dr. Shinoka leaves an enduring legacy in pediatric cardiac surgery, regenerative medicine and the countless lives he touched.

In Memoriam
Three members of the TEVG clean room team stand in blue scrubs.

Working Together for Breakthroughs That Change Children’s Lives

"From the time a child enters the hospital for their Fontan surgery to the time they go home, they will have interacted with more than 100 people. It’s important to recognize the many, many people who make the TEVG possible."

Christopher Breuer, MD